1-702-720-6310 info@microcapspecualtors.com

Chimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside – Seeking Alpha

May 17, 2017
admin
News

Chimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside
Seeking Alpha
Brincidofovir has shown in vitro efficacy against all of the families of DNA viruses that affect humans – cytomegalovirus (CMV), adenovirus, BK virus, and herpes simplex viruses. Brincidofovir should be approved as the first antiviral smallpox …

and more »

Apple Loop: New iPhone Design Leaks, Desirable iPhone Cancelled, Apple's Donald Trump Problem June 22, 2018
Taking a look back at another week of news from Cupertino, this week’s Apple Loop includes Apple’s critical decision over OLED and LCD iPhone screens, a clumsy iPhone design leaks, the cancelled iPhone SE 2, iOS 12 gifts for the iPad, an argument for three new MacBooks, questions over Apple’s wireless charging promise, and why […]
There's No Way Apple Isn't Building a Video-Streaming Service June 22, 2018
Finally.
Apple launches free repair program for MacBook and MacBook Pro keyboards June 22, 2018
Apple launched a service program for customers experiencing keyboard problems with some MacBook and MacBook Pro computers. Apple will replace some keys or entire keyboards if needed, for free. Apple AAPL just launched a free repair program for users with faulty keyboards on some MacBook and MacBook Pro computers.
Apple to Partner with Sesame Workshop for Children’s Programming June 22, 2018
Apple (AAPL) has made it clear that it’s serious about its streaming business. Apple has also partnered with Steven Spielberg to produce a spin-off of Amazing Stories, which he produced from 1985 to 1987. Last year, Apple hired producers Jamie Erlicht and Zack Van Amburg from Sony TV (SNE).
This is what the stock-market indicator with the best track record is telling us June 22, 2018
For some companies that have contracts with the federal government, rising detainee populations at the border could mean an increase in business. Follow their lead and craft your own investment policy statement to help avoid losing in the stock market.
Here’s what could happen to Apple’s average selling prices in the next iPhone cycle June 22, 2018
Apple Inc. has struggled to meet Wall Street’s expectations for iPhone units sales in recent quarters, but the company has surprised investors by getting consumers to pay ever more for its phones. The company’s strategy around its next iPhone launch will determine whether the trend continues. Morgan Stanley analyst Katy Huberty has weighed in on […]
Why Investors Are in a Frenzy over Sarepta Stock in June June 22, 2018
On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial on treating patients with Duchenne muscular dystrophy (or DMD) from the first three children dosed. DMD generally affects boys, and death typically occurs before age 30 in DMD patients. In all three patients, biopsies […]
Analyzing Sarepta’s Agreement with Myonexus Therapeutics June 22, 2018
Sarepta Therapeutics (SRPT) and Myonexus Therapeutics entered into a warrant to purchase Myonexus common stock on May 3. This agreement gives Sarepta the exclusive option to acquire Myonexus. Myonexus completes a successful biopsy analysis on all the patients in cohort two capable of providing a biopsy at the end of 60 days of Myonexus’s phase […]
A Look at Sarepta’s Exondys 51 Commercialization Efforts June 22, 2018
By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders. The company’s first product on the US market, the Exondys 51 injection, received accelerated approval from the US FDA in September 2016. The injection is targeted for treating Duchenne muscular dystrophy (or DMD).
How Sarepta’s Cash Flows Are Trending June 22, 2018
Sarepta Therapeutics (SRPT) spent $35.7 million on operating activities in Q1 2018. In comparison, the company spent $57.9 million in operating activities in Q1 2017. In Q1 2018, Sarepta Therapeutics spent $14.3 million on investing activities. It generated $210 million from investing activities in Q1 2017. Sarepta spent $12.2 million on the purchase of property […]

Pelosi says smartphone wouldn't exist without gov't

Insiders reveal how Boston moved to the forefront of the global fight against deadly diseases – Business Insider

This Week in Tech: Apple Inc. (AAPL), Twitter Inc (TWTR), and More